New York State Department of Health
Invivoscribe's LabPMM Nabs NY State Approval for MRD Assay
The company can now offer the FLT3 ITD MRD Assay in New York state to assess measurable residual disease to guide treatment for acute myeloid leukemia patients.
New York State DOH Approves Castle Biosciences' Barrett’s Esophagus Test
The TissueCypher assay is designed to identify patients with Barrett's esophagus who are at risk of progressing to esophageal cancer.
New York State DOH Approves Solvd Lab for Clinical PGx Testing
The company markets an assay intended to predict patients' risk of developing opioid use disorder, helping physicians tailor their use of these drugs.
New York State DOH Approves Biotia's AI-, Sequencing-Based Urinary Tract Infection Test
The laboratory-developed test uses shotgun metagenomic sequencing to identify pathogens that cause urinary tract infections.
NeoGenomics Wins New York State Approval for Solid Tumor, Lung Cancer NGS Tests
Although the approval is conditional, the company can now offer the tests for physicians and patients in the state.